Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

India

 

Indian lab chain Dr. Lal grows

Indian lab chain Dr. Lal Pathlabs is acquiring Delta RIA and Pathology Lab in Bhopal, Central India. Dr. Lal's IPO in December 2015 subscribed 33 times, raising Rs 190 crore (US$30m). Year-on-year sales in the first quarter of 2016 grew 15% to Rs 1977 crore (US$310m), with 26% EBITDA margin.

Private insurers in East Asia: Between a rock and a hard place

Private medical insurers face colossal problems in China, India and across South East Asia. At this month’s Asia Healthcare Summit in Singapore, they were better at describing the challenges of culture, fraud and overtreatment than they were at coming up with solutions.

Huge mental health treatment gap in China and India

The Lancet has reported that third of the global burden of disease for mental, neurological and substance use disorders occurs in India and China – more than in all high-income countries combined – yet 10% or less of people with mental disorders in these countries receive the needed treatment. Even for serious psychotic illness only 40% of Chinese had treatment from healthcare professionals. Both countries are about to engulfed by dementia as their populations age.

French not for profit SOS Group invests $150,000 in India homecare

Hyderabad based home healthcare player Life Circle Health Services has raised Rs1 crore ($150,000) from Groupe SOS. The subscription-based service for providing caregivers and nurses for chronically ill and bedridden patients will utilize the capital to expand its services in the Delhi region.

Thyrocare IPO subscribed 73 times over

Indian healthcare equities are still highly prized if the INR 480 crore (US$72m) IPO of the lab group, Thyrocare, is to be believed. The available shares were oversubscribed 73 times.

Outpatient sector to roar ahead in India

Single specialty chains offer the fastest growth in Indian healthcare says the CEO of MyDentist, Vikram Vora. Diabetes care, orthopaedics and rehab offer opportunities that remain untapped by private equity and are servicing the country’s growing elderly population.

Elite care is dead end in Asia

High-end hospitals in Asia find their margins compressed by high fixed costs and small markets, claims Abraar Mir, CEO of Quadria Capital. Whereas, EBITDA margins of 40% are achievable in affordable secondary care and demand is much greater. Acute care markets are booming, nonetheless, with groups like Mitra Keluarga adding 2,000 beds per year.

Find Us